Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting
Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability…
Ascentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual Meeting
ROCKVILLE, Md. and SUZHOU, China, April 19, 2026 (GLOBE NEWSWIRE) -- Ascentage…
Kaltura to Showcase Agentic Revenue Engagement Platform at Adobe Summit 2026, Demonstrating How Agentic AI Avatars and Content Intelligence Turn Static ABM Pages Into Real-Time Conversations
New York, New York, April 17, 2026 (GLOBE NEWSWIRE) -- Kaltura, Inc.…
Risen Energy Secures 1.2GW HJT Module Order from China Huaneng Group, Demonstrating Industry Leadership
NINGBO, China, April 15, 2026 /PRNewswire/ -- Recently, Risen Energy achieved a…
UniPat AI Launches EchoZ Prediction Model, Demonstrating Performance Beyond Human Traders on Polymarket
BEIJING, April 10, 2026 (GLOBE NEWSWIRE) -- UniPat AI announces benchmark…
Trogenix announces publication of breakthrough pre-clinical data in Nature demonstrating complete tumour eradication and durable protection in aggressive brain cancer model
A single-dose of Trogenix’s proprietary Synthetic Super-Enhancers achieved complete tumour elimination in…
Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026
March 27, 2026 10:30 ET | Source: Celldex Therapeutics, Inc. - Improvements…
MEXC Ranks No. 1 in XAUT Perpetual Volume Globally, Demonstrating Strong Liquidity and User Activity
VICTORIA, Seychelles, March 4, 2026 /PRNewswire/ -- MEXC, the world's fastest-growing digital asset…
Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease
March 01, 2026 09:45 ET | Source: Celldex Therapeutics, Inc. - Late…
Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran
BOSTON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT) today…
